New Issue: Orbital Catastrophe Ahead? Read Now

The Incredible, Medical Egg

Genetically modified chickens that produce medicines in their eggs may be the drug factories of the future

Join Our Community of Science Lovers!

The chicken egg has a storied history in medicine. Even today, millions of ordinary fertilized eggs are each punctured with a drill and injected with flu virus to make vaccines. Now, scientists at the same research institute that cloned Dolly the sheep have produced a genetically modified rooster whose female descendants lay eggs that produce medicines in place of a protein in egg whites.

Helen Sang of the Roslin Institute in Edinburgh, Scotland, and her colleagues used lentivirus to introduce a gene into freshly fertilized chicken embryos that trigger the production of various drugs rather than the protein ovalbumin, which normally makes up roughly 54 percent of egg whites. The researchers screened the resultant cockerels for one that produced the new gene in its semen. They then bred him with normal hens to produce a flock of chickens that carried the inserted gene thereby producing medicines in their egg's whites.

Tests of the flocks' eggs showed that they could produce either miR24--a monoclonal antibody used in treating melanoma--or interferon b-1a--an immune system protein used against multiple sclerosis, among other things--depending on which gene was inserted. The chickens produce 15 to 50 micrograms per milliliter of egg white, the researchers found, and though this is not as efficient as the expression of ovalbumin, it is efficient enough to allow for subsequent purification into therapeutic drugs. "We would expect the transgene not to be as efficient as the endogenous gene it was based on as only some of the regulatory elements were used and the transgene may be inserted in the chromosome at a position that does not favor anywhere near maximal expression," notes Roslin's Adrian Sherman, who also participated in the research. "I'm sure there is potential for improvement."


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Chicken eggs may prove a better way to producepharmaceuticals than other genetically modified products (such as goat milk) that have been previously explored. Chickens are easy to raise, produce numerous eggs, and are cheap to keep. And, after raising five generations of the modified birds, the researchers have observed no adverse health effects, according to the paper published online January 15 in Proceedings of the National Academy of Sciences USA.

Even though the therapeutic proteins worked as intended during in vitro assays, it will be years before the process is ready to be used to produce drugs for human consumption, researchers say. Roslin's chickens join a similar effort using stem cells developed by Origen Therapeutics. Regardless of which "biofactory" delivers drugs first, a new medicinal use for the venerable egg is now apparent.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe